Skip to main content

Hypogonadism, Male

Endocrinology
6
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
5
0
Early DiscoveryClinical DevelopmentMarket

Endocrinology is a $1.4B mature market dominated by legacy products and characterized by significant patent cliff exposure in the near-term.

$1.4B marketMature→ Stable30 products15 companies

Key Trends

  • Two blockbusters (FORTEO, SYNTHROID) approaching LOE with $780M combined spend
  • Growth phase products (ORGOVYX, TYMLOS) entering peak revenue years through 2040
  • Heavy trial activity (625 total) concentrated in Phase 3 and Phase 4 studies indicating established disease focus

Career Verdict

Endocrinology offers stability and specialized expertise but limited growth upside; best suited for professionals comfortable in mature markets seeking deep disease knowledge rather than explosive market expansion.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1FORTEODeclining
$425M
Eli Lilly and Company·LOE_APPROACHING
#2SYNTHROIDDeclining
$355M
AbbVie·LOE_APPROACHING
#3ORGOVYXStable
$277M
#4TYMLOSStable
$198M
Radius Health·PEAK13.7yr

Drug Class Breakdown

Parathyroid Hormone Analogs
$425M(30%)

LOE approaching; potential for new mechanisms

Thyroid Replacement (T3/T4 synthesis)
$379M(27%)

Mature, multiple generics; limited differentiation

GnRH Receptor Antagonists
$278M(20%)

Growth trajectory through 2037

Growth Hormone Analogs (Somatropin)
$27M(2%)

Stable; multiple biosimilars in market

CYP11B1 Inhibitors (Cortisol management)
$45M(3%)

Emerging niche for rare endocrine disorders

Career Outlook

Stable

Endocrinology offers deep specialization and stable employment but limited growth trajectory; market maturity and patent cliff exposure create restructuring risk for legacy product teams at large pharma. Career advancement depends on niche expertise (rare endocrine disorders, bone metabolism) and willingness to work at smaller or specialist biotech firms where hiring is concentrated. Compensation is moderate relative to other therapeutic areas, with Medical Affairs and Clinical Operations commanding premiums.

Breaking In

Prioritize roles at Neurocrine Biosciences or other specialist firms over large pharma to gain endocrinology depth; seek Clinical Operations or IT positions for better compensation and career stability.

For Experienced Professionals

Experienced professionals should pursue Medical Affairs or senior Clinical Operations roles (highest salaries) or consider pivoting to emerging indications (GnRH antagonists in non-prostate oncology, novel PTH mechanisms) to avoid legacy product decline.

In-Demand Skills

Regulatory affairs (navigating complex endocrinology indications and biosimilar pathways)Health economics and market access (managing mature market competition)Clinical trial operations (Phase 3/4 expertise given trial distribution)Real-world evidence and outcomes research (post-approval monitoring of legacy products)

Best For

Medical Science Liaison (strong compensation, focused disease education)Clinical Operations Manager (11% of roles, $210K avg)Regulatory Affairs Specialist (managing LOE transitions and generic competition)Market Access Analyst (managing pricing pressure on thyroid and bone products)

Hiring Landscape

$115K-$359K

Endocrinology hiring is concentrated at specialist biotech firms (Neurocrine: 126 jobs, 93% of available positions) rather than large pharma, indicating a niche market dynamic. IT roles dominate openings (51 jobs, $201K avg) followed by R&D (21 jobs, $120K avg), suggesting company-level digitalization and data infrastructure needs. Compensation ranges widely ($115K-$359K), with Medical Affairs offering premium salaries ($359K) but minimal openings (6 jobs).

135
Open Roles
3
Companies Hiring
5
Departments

Top Hiring Companies

3Stable

By Department

IT(38%)
$201K
Research & Development(16%)
$120K
Commercial(13%)
$115K
Clinical Operations(11%)
$210K
Medical Affairs(4%)
$359K

Limited total opportunity (135 jobs) concentrated at one biotech firm signals a tight job market; IT and Clinical Operations offer best compensation, but specialized endocrinology roles are scarce.

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Syneos Health
Syneos HealthNC - Morrisville
3 programs
1
2
SOV2012-F1Phase 31 trial
SOV2012-F1Phase 31 trial
Testosterone UndecanoatePhase 11 trial
Active Trials
NCT03973840Completed13Est. Jul 2018
NCT03198728Completed314Est. May 2020
NCT04467697Completed155Est. May 2020
Marius Pharmaceuticals
2 programs
2
SOV2012-F1Phase 3
SOV2012-F1Phase 3
Halozyme Therapeutics
1 program
1
Testosterone enanthatePhase 31 trial
Active Trials
NCT06689085Recruiting100Est. Mar 2030
Martin Pharmaceuticals
1 program
human chorionic gonadotropinN/A1 trial
Active Trials
NCT03254641Completed242Est. Oct 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Halozyme TherapeuticsTestosterone enanthate
Syneos HealthSOV2012-F1
Syneos HealthSOV2012-F1
Syneos HealthTestosterone Undecanoate
Martin Pharmaceuticalshuman chorionic gonadotropin

Clinical Trials (5)

Total enrollment: 824 patients across 5 trials

NCT06689085Halozyme TherapeuticsTestosterone enanthate

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Start: Mar 2025Est. completion: Mar 2030100 patients
Phase 3Recruiting

Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men

Start: Sep 2018Est. completion: May 2020155 patients
Phase 3Completed

Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

Start: Jul 2017Est. completion: May 2020314 patients
Phase 3Completed
NCT03973840Syneos HealthTestosterone Undecanoate

Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes

Start: Jul 2018Est. completion: Jul 201813 patients
Phase 1Completed
NCT03254641Martin Pharmaceuticalshuman chorionic gonadotropin

Calciotropic Effects After HCG Stimulation Test

Start: Apr 2017Est. completion: Oct 2021242 patients
N/ACompleted

Related Jobs in Endocrinology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 824 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.